In crowd­ed prostate can­cer mar­ket, Pfiz­er's Xtan­di notch­es third ap­proval for use in ear­li­er stage of dis­ease

Pfiz­er’s en­trenched an­dro­gen re­cep­tor in­hibitor Xtan­di has se­cured its third prostate can­cer ap­proval in a mar­ket flush with ri­vals.

On Mon­day, Pfiz­er and part­ner Astel­las an­nounced Xtan­di had scored FDA ap­proval in pa­tients with metasta­t­ic cas­tra­tion (or hor­mone)-sen­si­tive prostate can­cer (mC­SPC). It’s a form of prostate can­cer that has spread to oth­er parts of the body but still re­sponds to a med­ical or sur­gi­cal treat­ment that low­ers testos­terone — af­fect­ing rough­ly 40,000 men in the Unit­ed States cur­rent­ly. Xtan­di is now the on­ly oral FDA-ap­proved ther­a­py in three dis­tinct types of ad­vanced prostate can­cer, the com­pa­nies said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER